Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (218)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4756 results found
2021
∙
NIAC
NIAC Overview of Recommendations regarding booster doses of COVID-19 Vaccine for those aged 60 to 79 years
2021
∙
NIAC
NIAC Recommendations on booster doses of COVID-19 vaccine for healthcare workers, 16-59 years with underlying conditions, and all those 50-59 years
2021
∙
NIAC
NIAC Recommendations on booster doses of COVID-19 vaccine for those aged 16-49 years
2021
∙
NIAC
NIAC Recommendations on COVID-19 vaccination for children aged 5 to 11 Years
2021
∙
NIAC
NIAC UPDATED RECOMMENDATIONS FOR COVID-19 VACCINATION IN PREGNANCY
2021
NITAG-BF recommendation on the introduction of HEPATITIS B vaccine at birth in routine vaccination in Burkina Faso
2021
∙
Conseil Supérieur de la Santé (CSS)
Non-replicating viral vector vaccines and the Belgian COVID-19 vaccination strategy
2021
∙
NTAGI
NTAGI meeting minutes - 28 May 2021
2021
∙
JCVI
Optimising the COVID-19 vaccination programme for maximum short-term impact
2021
∙
ACIP
Overview of Janssen’s Single-Dose COVID-19 Vaccine, Ad26.COV2.S
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register